OBJECTIVES: To outline demographic, clinical features, and treatment patterns in a contemporary Chinese cohort of Mantle Cell Lymphoma (MCL) patients.

METHODS: This retrospective study utilized integrated regional electronic healthcare records spanning from 2004 to 2022. The sample comprised newly diagnosed MCL patients with continuous healthcare interactions, setting the first recorded MCL diagnosis date as the index. Exclusions involved individuals under 18 years old and those lacking information on age and sex. Data encompassed patient demographics, MCL stage at diagnosis, treatment regimens, and clinical outcomes.

RESULTS: The study identified 475 MCL cases. Average age was 58 at , with 123 (25.9%) females, 227 (96.0%) at Ann Arbor stage III/IV, and 139 (29.3%) covered by insurance. Baseline comorbidities included hypertension (23.6%), pulmonary infection (21.9%), and diabetes (13.6%). Over a median follow-up of 6.1 [18.2(41.8)] months from the index date, 250 (54.0%) patients received MCL-specific treatment, with 57 (22.8%), 138 (55.2%), and 45 (18.0%) undergoing chemotherapy, immunochemotherapy, and targeted therapy in the first-line treatment, respectively. Among those receiving targeted therapy, 44 (50.0%), 40 (45.5%), 1 (1.1%), and 3 (3.4%) were treated with ibrutinib, zanubrutinib, orelabrutinib, and venetoclax, respectively. The proportion receiving BTKi increased from 2.2% to 44.0% between 2017 and 2022. Furthermore, 43 (9.1%) and 4 (0.8%) patients underwent stem cell transplantation and CAR-T therapy, respectively. The median overall survival (OS) from initiation of first-line (1L) treatment was 72.4 months, with 1-year and 3-year survival rates of 95.3% and 86.9% from initial diagnosis and 78.6% and 71.4% from 1L treatment initiation.

CONCLUSIONS: This real-world study, utilizing regional healthcare data, revealed distinctive demographic, clinical, and tumor-related characteristics. The findings provide a comprehensive overview of MCL management in China, suggesting areas for clinical practice improvement and research opportunities as newer therapies continue to emerge. Future studies should address unmet needs in MCL patients to ensure better access to novel treatments.